EFFECT OF IRBESARTAN IN HYPERTENSIVES WITH TYPE II DIABETES AND NEPHROPATHY

厄贝沙坦对高血压合并 II 型糖尿病和肾病的影响

• 批准号: 6275987
• 负责人: REBECCA L HEGEMAN
• 金额: $ 1.92万
• 依托单位: UNIVERSITY OF IOWA
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6275987
• 关键词: amlodipine; biphenyl compounds; calcium channel blockers; clinical research; creatinine; diabetic nephropathy; human morbidity; human subject; human therapy evaluation; hypertension; noninsulin dependent diabetes mellitus; pharmacokinetics; placebos

The goal of the study is to determine whether irbesartan, an angiotensin II receptor antagonist, will increase the time to doubling of serum creatinine, end-stage renal disease or death compared to placebo or amlodipine in hypertensive patients with diabetic nephropathy.

这项研究的目标是确定血管紧张素转换酶伊贝沙坦 II受体拮抗剂，会增加血清翻倍的时间 肌酐、终末期肾病或死亡与安慰剂或 氨氯地平在高血压合并糖尿病肾病患者中的应用